Our results suggest that the EML4-ALK translocation frequency differed in the adenocarcinoma group compared to the non-adenocarcinoma group (OR [95% CI] = 2.07 [1.11, 3.84], Z = 2.30; P<0.05) (Figure 6B). This evidence concerns the gene ALK and adenocarcinoma.